Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world.
  • Posted by Mariel Metcalfe
  • February 27, 2018
  • Articles

Bringing sufferers out of the shadows – Reducing the emotional impact of living with Atopic Dermatitis

Bringing sufferers out of the shadows – Reducing the emotional impact of living with Atopic Dermatitis

You can probably remember at least one of your friends in school who was always scratching and suffered from red, scaly skin rashes, perhaps on their elbows or backs of their knees, and if they were really unlucky, on their face? This child may have disliked going to the swimming pool and particularly suffered from flare-ups during cold winter or hot summer months. They might have tried to cover up their skin with long-sleeved clothing, or hide their face to avoid being stared at.
 

read more »

  • Posted by Marc Yates
  • February 27, 2018
  • Articles

Good intentions, bad habits: Reforming mental healthcare in Latin America and the Caribbean

Good intentions, bad habits: Reforming mental healthcare in Latin America and the Caribbean

Published in eyeforpharma April 2018 by Marc Yates

The Latin America and Caribbean (LAC) region is a vast patchwork of countries, cultures and ethnicities, with a total population of more than 645 million, ranging from 209 million-plus in Brazil to islands with fewer than 100,000 inhabitants. The diversity is also economic. Recent years have seen marked improvements in income distribution and a burgeoning middle class, particularly in countries such as Argentina, Bolivia, Ecuador, Peru and Nicaragua. Yet Latin America and the Caribbean remains the region with the highest levels of income inequality worldwide.  All of this has a significant bearing on the state of mental health in Latin America, where good intentions and genuine progress in reforming infrastructure and attitudes are clouded by treatment gaps, inadequate funding, over-centralisation, meagre human resources and persistent stigmatisation.

read more »

  • Posted by Marc Yates
  • January 22, 2018
  • Articles

Out of the shadows: Mental health in the Asia Pacific region

Out of the shadows: Mental health in the Asia Pacific region

Published in eyeforpharma February 2018 by Marc Yates

Mental health has been a peripheral issue in emerging markets for a long time, despite the severe impact it can have, not only on those directly affected but also on families, carers, social cohesion, and economic development. Fortunately, mental health is starting to get more attention, but there is still a widespread tendency to stigmatise and discriminate against people suffering with a mental illness. They are often considered as dangerous and aggressive which in turn increases the social distance.
Is there an opportunity for pharma to do more? In the first of a series of articles exploring mental health in emerging markets we take an in-depth look at the situation in Asia where problems arising from ill mental health are the second largest contributor to years lost to disability (YL:D). 

read more »

  • Posted by Rachel Howard
  • January 18, 2018
  • Articles

New opportunities in emerging markets

New opportunities in emerging markets

Published in Pharma Exec January 2018 by Rachel Howard

The next billion patientsUntil recently, multinational pharmaceutical and life sciences companies have focused their clinical research efforts/clinical development programs almost exclusively on mature markets: North America, Europe and Japan in particular. However, rapid changes are underway in emerging markets. Firstly, we are seeing an expanding middle class. Virtually every emerging market, from Indonesia to Mexico and from China to Brazil, is witnessing an increase in the proportion of patients who now qualify as middle class, and wealth is increasing commensurately, enabling more individuals to afford essential care or purchase private health insurance. This growth is set to continue. In parallel, we are seeing an increased focus among emerging market governments on public healthcare reform: expanding their populations’ access to medicines by establishing universal healthcare coverage (such as JKN in Indonesia and Seguro Popular in Mexico) and deepening access by expanding formularies to include more drugs (despite these often being set in the context of aggressive cost containment measures).  Greater purchasing power and improved market access are growing the opportunity for innovative medicines in these markets.  The vast populations of many emerging markets mean they constitute a high proportion of the world’s "next billion patients", which pharma simply cannot afford to…

read more »

  • Posted by Harriet Kozak
  • November 17, 2017
  • Articles

Medical Marijuana: A Challenge to Traditional Pain Relief?

Medical Marijuana: A Challenge to Traditional Pain Relief?

Published in Pharmaceutical Executive November 2017

Medical use of marijuana for a broad range of conditions is expanding rapidly in the US, as legalization gathers pace and investors flock to a booming market. A January 2017 report for the National Academies of Sciences, Engineering and Medicine (NASEM) found substantial or conclusive evidence of marijuana’s therapeutic benefit in chronic pain, multiple sclerosis and chemotherapy-induced nausea and vomiting. Other, more tentative US state-approved indications include diabetes, glaucoma, epilepsy, migraine, post-traumatic stress disorder, hepatitis C, Crohn’s disease, Parkinson’s disease and Tourette syndrome.

read more »